



DEPARTMENT OF ECONOMIC SECURITY

Your Partner For A Stronger Arizona

DIVISION OF DEVELOPMENTAL DISABILITIES

Sent on Behalf of DES/DDD

POLICY UPDATE

Target Audience - Qualified Vendors and Providers

Transmittal Date - 07/13/2022

The DDD Policy Unit published a new policy on Wednesday July 6, 2022. The policy is available on the Division's [Policy webpage](#).

NEW POLICIES

[Division Medical Policy Manual 1024 Drug Utilization Review](#)

This policy was developed to align with AHCCCS Medical Policy Manual (AMPM) Chapter 1024 Drug Utilization Review. This is a new Policy that defines the Division's responsibility for oversight of the Drug Utilization Review (DUR) program that is developed and implemented by the AdSS.

[AdSS Medical Policy Manual 1024 Drug Utilization Review](#)

This policy has been developed to align with AHCCCS Medical Policy Manual (AMPM) 1024 Drug Utilization Review. This is a new policy that includes the requirement for the AdSS to develop an integrated system related to Drug utilization Review (DUR) and having policies and procedures for retrospective, concurrent and prospective processes, coverage criteria and processes for DUR programs.

REVISED POLICIES

[Division Medical 320-M Medical Marijuana and CBD Oil Products](#)

This policy was revised to clarify the Division and AdSS' coverage of CBD oil and state prescription medications containing THC/CBD are covered and may be administered. Revisions were made to the Policy to state that the Division does not cover medical marijuana or CBD oil products and under no circumstances may Division staff or contractors administer or store medical marijuana or CBD oil products. The policy establishes requirements for the coverage and use of medical marijuana and all cannabidiol (CBD) products (regardless of plant derivation), the Division will cover FDA approved cannabidiol products (Epidiolex and Marinol).

[AdSS Medical 320-M Medical Marijuana and CBD Oil Products](#)

This policy was revised to clarify the Division and AdSS' coverage of CBD oil and state prescription medications containing THC/CBD are covered and may be administered. Revisions were made to the Policy to state that the Division does not cover medical marijuana or CBD oil products and under no circumstances may Division staff or contractors administer or store medical marijuana or CBD oil products. The policy establishes requirements for the coverage and use of medical marijuana and all cannabidiol (CBD) products (regardless of plant derivation), the Division will cover FDA approved cannabidiol products (Epidiolex and Marinol).

[Provider Manual Chapter 27 Peer Review and Inter-Rater Reliability](#)

This provider manual chapter has been revised to clarify language and revise the format. It contains no substantive changes.

[Provider Manual Chapter 48 Credentialing of Contracted Providers](#)

This provider manual chapter has been revised to clarify language and revise the format. It contains no substantive changes.

POLICY PUBLIC COMMENT

The Division is currently accepting public comments regarding Division policies. The policy revisions can be found on the [Policy page](#) of the Division's website. This form, <https://forms.gle/4MGCsdyKTRPJna3m9>, can be used to submit public comments.